Document:

cy22q2ex41thirdsupplemen

THIRD SUPPLEMENTAL INDENTURE  Third Supplemental Indenture, dated as of May 25, 2022, (this “Third  Supplemental Indenture”) among Perrigo Company plc, an Irish public limited company (the  “Company”), Perrigo Investments, LLC, Perrigo Investments Capital, Inc., Athena  Neurosciences, LLC, CP Kayak Holdings, Inc., Elan Pharmaceuticals, LLC, PBM Nutritionals,  LLC, Perrigo Diabetes Care, LLC, Perrigo International Holdings II, Inc., Perrigo New York,  Inc., Perrigo Oral Health Care Holdings, Inc., Ranir Global Holdings, LLC, Ranir, LLC, PBM  Products, LLC, PBM Foods, LLC, PBM Canada Holdings, LLC, PBM China Holdings, LLC,  Perrigo Mexico Investment Holdings, LLC, Perrigo International Holdings, LLC, Perrigo  Florida, Inc., Perrigo Direct, Inc., Perrigo Americas Holdings, Inc., Gr8ness, LLC, L. Perrigo  Company, Perrigo Company, Perrigo Finance (US) LLC, Perrigo International, Inc., Perrigo  Management Company, Perrigo Research & Development Company, Perrigo Sales Corporation,  PMI Branded Pharmaceuticals, Inc., Galpharm Healthcare Limited, Galpharm International  Limited, Omega Pharma Limited, Perrigo Pharma Limited, Perrigo UK Acquisition Limited,  Ranir (Holdings) Limited, The Learning Pharmacy Ltd., Wrafton Laboratories Limited, Ranir  Limited, Solent Oral Care LTD, Kiteacre Limited, Biover NV, Jaico R.D.P. NV, Medgenix  Benelux NV, OCE-BIO BV, Omega Pharma Belgium NV, Omega Pharma Capital NV, Omega  Pharma Innovation & Development NV, Omega Pharma International NV, Omega Pharma  Trading NV, Perrigo Europe Invest NV, Perrigo Holding NV, Perrigo Finance Unlimited  Company, Chefaro Ireland Designated Activity Company, Habsont Unlimited Company, Perrigo  Corporation Designated Activity Company, Perrigo Holdings Unlimited Company, Perrigo  International Finance Designated Activity Company, Perrigo Ireland 1 Designated Activity  Company, Perrigo Ireland 10 Unlimited Company, Perrigo Ireland 2 Designated Activity  Company, Perrigo Ireland 3 Designated Activity Company, Perrigo Ireland 8 Designated  Activity Company, Perrigo Ireland 4 Unlimited Company, Perrigo Ireland 5 Unlimited  Company, Perrigo Ireland 6 Unlimited Company, Perrigo Pharma International Designated  Activity Company, Perrigo Ireland Management Designated Activity Company, Perrigo Ireland  9 Unlimited Company, Perrigo Ireland 11 Designated Activity Company, Perrigo Ireland 12  Designated Activity Company, Perrigo Ireland 13 Designated Activity Company, Perrigo  Science One Designated Activity Company, Perrigo Science Eight Unlimited Company and  Omega Teknika Designated Activity Company (each a “New Perrigo Guarantor”, and  collectively the “New Perrigo Guarantors”) and Wells Fargo Bank, National Association, as  trustee (the “Trustee”).  W I T N E S S E T H  WHEREAS, the Company, the Guarantors (as defined in the Indenture) and the  Trustee are parties to an indenture (the “Indenture”), dated as of November 8, 2013, as  supplemented by the First Supplemental Indenture among the Company, the Initial Guarantors  (as defined therein), the Perrigo Guarantors (as defined therein) and the Trustee, dated as of  December 18, 2013, and the Second Supplemental Indenture among the Company, the Elan  Guarantors (as defined therein) and the Trustee, dated as of February 14, 2014, providing for  the issuance by the Company of $500,000,000 aggregate principal amount of 1.30% Senior  Exhibit 4.1 

 

        Notes due 2016 (the “2016 Notes”), $600,000,000 aggregate principal amount of 2.30%  Senior Notes due 2018 (the “2018 Notes”), $800,000,000 aggregate principal amount of  4.00% Senior Notes due 2023 (the “2023 Notes”) and $400,000,000 aggregate principal  amount of 5.30% Senior Notes due 2043 (the “2043 Notes” and, together with the 2016 Notes,  the 2018 Notes and the 2023 Notes, the “Notes”);  WHEREAS, the Initial Guarantors, Perrigo Guarantors and Elan Guarantors are  no longer Guarantors under the Notes; the 2016 Notes, the 2018 Notes and the 2023 Notes are  no longer outstanding;   WHEREAS, the New Perrigo Guarantors now wish to provide an irrevocable  and unconditional guarantee in respect of the 2043 Notes and the guarantees of each New  Perrigo Guarantor will constitute a direct benefit to such New Perrigo Guarantor and will be in  furtherance of the corporate purposes of such New Perrigo Guarantor or necessary or  convenient to the conduct, promotion or attainment of the business of such New Perrigo  Guarantor and, accordingly, in consideration therefor, each New Perrigo Guarantor is willing  to guarantee the 2043 Notes on the terms set forth herein;   WHEREAS, Section 901(15) of the Indenture provides that the Trustee is  authorized to execute and deliver this Third Supplemental Indenture without the consent of the  Holders of the 2043 Notes to provide for the guarantee of the 2043 Notes;  WHEREAS, pursuant to Section 903 of the Indenture, the Trustee is authorized to  execute and deliver this Third Supplemental Indenture.  NOW THEREFORE, in consideration of the foregoing and for other good and  valuable consideration, the receipt of which is hereby acknowledged, the parties mutually  covenant and agree for the equal and ratable benefit of the Holders of the 2043 Notes as  follows:  (1) Capitalized Terms. Capitalized terms used herein without definition shall  have the meanings assigned to them in the Indenture.  (2) Agreement to be Bound. Each New Perrigo Guarantor hereby becomes a  party to the Indenture as a Guarantor and as such will have all of the rights and be subject to all  of the obligations and agreements of a Guarantor under the Indenture.  (3) Guarantee. Each New Perrigo Guarantor agrees, on a joint and several  basis, to fully, unconditionally and irrevocably Guarantee to each Holder of the 2043 Notes and  the Trustee the obligations of the Company pursuant to and as set forth in Article Seventeen of  the Indenture. In addition, in respect of each New Perrigo Guarantor incorporated or existing  under Belgian law (each a “Belgian Guarantor”) its obligations and the granting of its Guarantee  shall be limited as follows:    

 

        (a) the Guarantee granted by any Belgian Guarantor shall not include and shall not  extend to cover any payment obligation arising out of amounts used to fund  directly or indirectly the acquisition of shares of such Belgian Guarantor to the  extent that by assuming such obligation the Belgian Guarantor would be deemed  to be providing prohibited financial assistance to the acquisition of its own shares  or capital participations, as prohibited under Article 5:152 or Article 7:227 (as  applicable) of the Belgian Code of Companies and Associations; and    (b) the aggregate liability of a Belgian Guarantor for the obligations of any  Loan  Party, which is not a direct or indirect Subsidiary of that Belgian Guarantor,  shall  at all times be limited to an amount not exceeding the greater of:    (i) an amount equal to 90% of that Belgian Guarantor’s net assets (eigen  vermogen/capitaux propres) as determined in Article 5:142 or Article  7:212 (as applicable) of the Belgian Code of Companies and Associations,  but not taking intra group debt into account as debt, as calculated on the  basis of its most recent financial statements on the date of which a demand  for payment is made;     (ii) an amount equal to 90% of that Belgian Guarantor’s net assets (eigen  vermogen/capitaux propres) as determined in accordance with Article  5:142 or Article 7:212 (as applicable) of the Belgian Code of Companies  and Associations, but not taking intra group debt into account as debt, as  calculated on the basis of its most recent financial statements on the date  of this Third Supplemental Indenture; and    (iii) the aggregate amount of all moneys, either directly or through one or more  members of the Group made available to (i) that Belgian Guarantor and  (ii) the Subsidiaries of that Belgian Guarantor, in each case, irrespective of  whether retained or on-lent by the Belgian Guarantor or its Subsidiary.  (4) Release of Guarantee.    (a) The Guarantee of each New Perrigo Guarantor shall be automatically and  unconditionally released (and thereupon shall terminate and be discharged and be  of no further force and effect) upon:     (i) the consummation of any transaction permitted under the Indenture  (including a sale, transfer, disposition or distribution of such Guarantor to a Person that is  not the Company or one of its Subsidiaries) resulting in such Guarantor ceasing to be a  Subsidiary;    (ii) upon the merger or consolidation of any Guarantor with and into the  Company or upon the liquidation of such Guarantor following the transfer of all of its  assets to the Company;  

 

        (iii) the release or discharge of the guarantee by such Guarantor of all  outstanding indebtedness under the Permanent Credit Facilities (as defined in  the Indenture); or  (iv) the exercise by the Company of its legal defeasance option or covenant  defeasance option pursuant to Article Fourteen of the Indenture or the discharge of the  Company’s obligations under the Indenture in accordance with the terms of the  Indenture; and  (b) such Guarantor delivering to the Trustee an Officers’ Certificate of such  Guarantor or the Company and an Opinion of Counsel, each stating that all conditions precedent  provided for in the Indenture relating to such transaction or release and discharge have been  complied with.    (5) Severability. In case any provision of this Third Supplemental Indenture  shall be invalid, illegal or unenforceable, the validity, legality, and enforceability of the  remaining provisions shall not in any way be affected or impaired thereby.    (6) No Recourse Against Others. No director, officer, employee, incorporator  or stockholder of a New Perrigo Guarantor shall have any liability for any obligations of the  Company or the Guarantors (including a New Perrigo Guarantor) under the 2043 Notes, any  Guarantees, the Indenture or this Third Supplemental Indenture or for any claim based on, in  respect of, or by reason of, such obligations or their creation. Each Holder by accepting 2043  Notes waives and releases all such liability. The waiver and release are part of the consideration  for issuance of the 2043 Notes.    (7) Effect of Third Supplemental Indenture; Conflicts With Indenture. This  Third Supplemental Indenture is executed by the New Perrigo Guarantors, the Company and the  Trustee upon the Company’s request, pursuant to the provisions of the Indenture, and the terms  and conditions hereof shall be deemed to be part of the Indenture for all purposes. The Indenture,  as amended and supplemented by this Third Supplemental Indenture, is in all respects hereby  adopted, ratified and confirmed. Notwithstanding the foregoing, to the extent that any of the  terms of this Third Supplemental Indenture are inconsistent with, or conflict with, the terms of  the Indenture, the terms of this Third Supplemental Indenture shall govern.     (8) Trustee Disclaimer. The recitals contained in this Third Supplemental  Indenture shall be taken as the statements of the Company and the New Perrigo Guarantors and  the Trustee assumes no responsibility for their correctness. The Trustee makes no representations  as to and shall not be responsible for the validity or sufficiency of this Third Supplemental  Indenture or the Guarantees of the New Perrigo Guarantors. All rights, protections, privileges,  indemnities and benefits granted or afforded to the Trustee under the Indenture shall be deemed  incorporated herein by this reference and shall be deemed applicable to all actions taken,  suffered or omitted by the Trustee under this Third Supplemental Indenture. The Company  hereby confirms to the Trustee that this Supplemental Indenture has not resulted in a material  modification of the 2023 Notes and the 2043 Notes for Foreign Account Tax Compliance Act  (“FATCA”) purposes.    

 

        (9) Counterparts; Electronic Signatures. This Third Supplemental Indenture  may be executed in any number of counterparts, each of which shall be an original but all of  which together shall constitute one instrument. Each counterparty may consist of a number of  copies hereof, each signed by less than all, but together signed by all, of the parties hereto. The  exchange of copies of this Third Supplemental Indenture and of signature pages by facsimile or  PDF transmission shall constitute effective execution and delivery of this Third Supplemental  Indenture as to the parties hereto and may be used in lieu of the original Third Supplemental  Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall  be deemed to be their original signatures for all purposes. This Third Supplemental Indenture  and any certificate, agreement or other document to be signed in connection with this  Supplemental Indenture and the transactions contemplated hereby shall be valid, binding, and  enforceable against a party when executed and delivered by an authorized individual on behalf of  the party by means of (i) an original manual signature; (ii) a faxed, scanned, or photocopied  manual signature, or (iii) any other electronic signature permitted by the federal Electronic  Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic  Transactions Act, and/or any other relevant electronic signatures law, including any relevant  provisions of the UCC (collectively, “Signature Law”), in each case to the extent applicable.  Each faxed, scanned, or photocopied manual signature, or other electronic signature, shall for all  purposes have the same validity, legal effect, and admissibility in evidence as an original manual  signature. Each party hereto shall be entitled to conclusively rely upon, and shall have no  liability with respect to, any faxed, scanned, or photocopied manual signature, or other electronic  signature, of any other party and shall have no duty to investigate, confirm or otherwise verify  the validity or authenticity thereof. This Third Supplemental Indenture may be executed in any  number of counterparts, each of which shall be deemed to be an original, but such counterparts  shall, together, constitute one and the same instrument. For the avoidance of doubt, original  manual signatures shall be used for execution or indorsement of writings when required under  the UCC or other Signature Law due to the character or intended character of the writings.    (10) Headings. The headings of the sections in this Third Supplemental  Indenture are for convenience of reference only and shall not be deemed to alter or affect the  meaning or interpretation of any provisions hereof.  [Signature Pages Follow]    

 

  [Signature Page to Third Supplemental Indenture]  IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental  Indenture to be duly executed, all as of the date first above written.  Perrigo Company plc    By:                                                    Name:  Sonia A. Hollies       Title:  Senior Vice President and Treasurer  

 

  [Signature Page to Third Supplemental Indenture]  IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental  Indenture to be duly executed, all as of the date first above written.           Perrigo Investments, LLC           Perrigo Investments Capital, Inc.         CP Kayak Holdings, Inc.           Elan Pharmaceuticals, LLC           PBM Nutritionals, LLC           Perrigo Diabetes Care, LLC           Perrigo International Holdings II, Inc.           Perrigo New York, Inc.  Perrigo Oral Health Care Holdings, Inc.  Ranir Global Holdings, LLC  Ranir, LLC  PBM Products, LLC  PBM Foods, LLC  PBM Canada Holdings, LLC  PBM China Holdings, LLC  Perrigo Mexico Investment Holdings, LLC  Perrigo International Holdings, LLC  Perrigo Florida, Inc.  Perrigo Direct, Inc.  Perrigo Americas Holdings, Inc.  Gr8ness, LLC  L. Perrigo Company  Perrigo Company   Perrigo Finance (US) LLC  Perrigo International, Inc.  Perrigo Management Company  Perrigo Research & Development Company  Perrigo Sales Corporation  PMI Branded Pharmaceuticals, Inc.      By:    Name: Sonia A. Hollies   Title:   Senior Vice President and  Treasurer              Athena Neurosciences, LLC      By:    Name: Sonia A. Hollies   Title:   President and Treasurercy22q2ex42fourthsuppleme

SUPPLEMENTAL INDENTURE NO. 4  Supplemental Indenture No. 4, dated as of May 25, 2022, (this “Fourth  Supplemental Indenture”) among Perrigo Finance Unlimited Company, an Irish public unlimited  company (formerly, Perrigo Finance plc) (the “Company”), Perrigo Company plc, an Irish public  limited company (the “Parent Guarantor”), Perrigo Investments, LLC, Perrigo Investments  Capital, Inc., Athena Neurosciences, LLC, CP Kayak Holdings, Inc., Elan Pharmaceuticals,  LLC, PBM Nutritionals, LLC, Perrigo Diabetes Care, LLC, Perrigo International Holdings II,  Inc., Perrigo New York, Inc., Perrigo Oral Health Care Holdings, Inc., Ranir Global Holdings,  LLC, Ranir, LLC, PBM Products, LLC, PBM Foods, LLC, PBM Canada Holdings, LLC, PBM  China Holdings, LLC, Perrigo Mexico Investment Holdings, LLC, Perrigo International  Holdings, LLC, Perrigo Florida, Inc., Perrigo Direct, Inc., Perrigo Americas Holdings, Inc.,  Gr8ness, LLC, L. Perrigo Company, Perrigo Company, Perrigo Finance (US) LLC, Perrigo  International, Inc., Perrigo Management Company, Perrigo Research & Development Company,  Perrigo Sales Corporation, PMI Branded Pharmaceuticals, Inc., Galpharm Healthcare Limited,  Galpharm International Limited, Omega Pharma Limited, Perrigo Pharma Limited, Perrigo UK  Acquisition Limited, Ranir (Holdings) Limited, The Learning Pharmacy Ltd., Wrafton  Laboratories Limited, Ranir Limited, Solent Oral Care LTD, Kiteacre Limited, Biover NV, Jaico  R.D.P. NV, Medgenix Benelux NV, OCE-BIO BV, Omega Pharma Belgium NV, Omega Pharma Capital NV, Omega Pharma Innovation & Development NV, Omega Pharma International NV, Omega Pharma Trading NV, Perrigo Europe Invest NV, Perrigo Holding NV, Perrigo Finance Unlimited Company, Chefaro Ireland Designated Activity Company, Habsont Unlimited Company, Perrigo Corporation Designated Activity Company, Perrigo Holdings Unlimited Company, Perrigo International Finance Designated Activity Company, Perrigo Ireland 1 Designated Activity Company, Perrigo Ireland 10 Unlimited Company, Perrigo Ireland 2 Designated Activity Company, Perrigo Ireland 3 Designated Activity Company, Perrigo Ireland 8 Designated Activity Company, Perrigo Ireland 4 Unlimited Company, Perrigo Ireland 5 Unlimited Company, Perrigo Ireland 6 Unlimited Company, Perrigo Pharma International Designated Activity Company, Perrigo Ireland Management Designated Activity Company, Perrigo Ireland 9 Unlimited Company, Perrigo Ireland 11 Designated Activity Company, Perrigo Ireland 12 Designated Activity Company, Perrigo Ireland 13 Designated Activity Company, Perrigo Science One Designated Activity Company, Perrigo Science Eight Unlimited Company and Omega Teknika Designated Activity Company (each a “New Perrigo Guarantor”, and collectively the “New Perrigo Guarantors”) and Wells Fargo Bank, National Association, as trustee (the “Trustee”). W I T N E S S E T H  WHEREAS, the Company, the Parent Guarantor and the Trustee are parties to  an indenture (the “Indenture”), dated as of December 2, 2014, as supplemented by the  Supplemental Indenture No. 1 among the Company, the Parent Guarantor and the Trustee,  dated as of December 2, 2014, providing for the issuance by the Company of $500,000,000  aggregate principal amount of 3.500% Senior Notes due 2021 (the “First 2021 Notes”),  $700,000,000 aggregate principal amount of 3.900% Senior Notes due 2024 (the “2024  Exhibit 4.2 

 

Notes”) and $400,000,000 aggregate principal amount of 4.900% Senior Notes due 2044 (the  “2044 Notes”); the Supplemental Indenture No. 2 among the Company, the Parent Guarantor  and the Trustee, dated as of March 10, 2016 providing for the issuance by the Company of  $500,000,000 aggregate principal amount of 3.500% Senior Notes due 2021 (the “Second  2021 Notes”) and $700,000,000 aggregate principal amount of 4.375% Senior Notes due 2026  (the “2026 Notes”) and Supplemental Indenture No. 3 among the Company, the Parent  Guarantor and the Trustee, dated as of June 19, 2020, providing for the issuance by the  Company of $750,000,000 aggregate principal amount of 3.150% Senior Notes due 2030 (the  “2030 Notes” and, together with the First 2021 Notes, the 2024 Notes, the 2044 Notes, the  Second 2021 Notes, the 2026 Notes and the 2030 Notes, the “Notes”);  WHEREAS, the First 2021 Notes and the Second 2021 Notes are no longer  outstanding;   WHEREAS, the New Perrigo Guarantors now wish to provide an irrevocable  and unconditional guarantee in respect of the 2024 Notes, the 2026 Notes, the 2030 Notes and  the 2044 Notes (collectively, the “Outstanding Notes”) and the guarantees of each New  Perrigo Guarantor will constitute a direct benefit to such New Perrigo Guarantor and will be in  furtherance of the corporate purposes of such New Perrigo Guarantor or necessary or  convenient to the conduct, promotion or attainment of the business of such New Perrigo  Guarantor and, accordingly, in consideration therefor, each New Perrigo Guarantor is willing  to guarantee the Outstanding Notes on the terms set forth herein;  WHEREAS, Section 9.1(o) of the Indenture provides that the Trustee is  authorized to execute and deliver this Fourth Supplemental Indenture without the consent of  the Holders of the Outstanding Notes to provide for the guarantee and any guarantor release  provisions of the Outstanding Notes;  WHEREAS, pursuant to Section 9.3 of the Indenture, the Trustee is authorized to  execute and deliver this Fourth Supplemental Indenture;  NOW THEREFORE, in consideration of the foregoing and for other good and  valuable consideration, the receipt of which is hereby acknowledged, the parties mutually  covenant and agree for the equal and ratable benefit of the Holders of the Outstanding Notes  as follows:  (1) Capitalized Terms. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.  (2) Agreement to be Bound. Each New Perrigo Guarantor hereby becomes a party to the Indenture as a Guarantor and as such will have all of the rights and be subject to all  of the obligations and agreements of a Guarantor under the Indenture.  (3) Guarantee. Each New Perrigo Guarantor agrees, on a joint and several basis, with the existing Guarantors, to fully, unconditionally and irrevocably Guarantee to each  Holder of the Outstanding Notes and the Trustee the obligations of the Company pursuant to  and as set forth in Article Fourteen of the Indenture. Notwithstanding Section 2.1,  

 

        Section 2.4(a), Section 3.3, Section 14.2 and any other provisions of the Indenture, and solely  for purposes of the Outstanding Notes, the New Perrigo Guarantors, the Company, the Parent  Guarantor and the Trustee hereby agree that notwithstanding the absence of the endorsement of  any notation of such Guarantee on the Outstanding Notes (i) the Guarantee of the New Perrigo  Guarantors shall remain in full force and effect and (ii) all references in the Indenture to any  Guarantee endorsed on the Outstanding Notes shall be deemed to refer to the Guarantee of the  New Perrigo Guarantors contained in this Section 3 of this Fourth Supplemental Indenture. In  addition, in respect of each New Perrigo Guarantor incorporated or existing under Belgian law  (each a “Belgian Guarantor”) its obligations and the granting of its Guarantee shall be limited as  follows:  (a) the Guarantee granted by any Belgian Guarantor shall not include and shall not  extend to cover any payment obligation arising out of amounts used to fund directly or  indirectly the acquisition of shares of such Belgian Guarantor to the extent that by  assuming such obligation the Belgian Guarantor would be deemed to be providing  prohibited financial assistance to the acquisition of its own shares or capital  participations, as prohibited under Article 5:152 or Article 7:227 (as applicable) of the  Belgian Code of Companies and Associations; and    (b) the aggregate liability of a Belgian Guarantor for the obligations of any  Loan  Party, which is not a direct or indirect Subsidiary of that Belgian Guarantor shall at all  times be limited to an amount not exceeding the greater of:  (i) an amount equal to 90% of that Belgian Guarantor’s net assets (eigen  vermogen/capitaux propres) as determined in Article 5:142 or Article 7:212 (as  applicable) of the Belgian Code of Companies and Associations, but not taking intra  group debt into account as debt, as calculated on the basis of its most recent financial  statements on the date of which a demand for payment is made;     (ii) an amount equal to 90% of that Belgian Guarantor’s net assets (eigen  vermogen/capitaux propres) as determined in accordance with Article 5:142 or Article  7:212 (as applicable) of the Belgian Code of Companies and Associations, but not taking  intra group debt into account as debt, as calculated on the basis of its most recent  financial statements on the date of this Third Supplemental Indenture; and    (iii) the aggregate amount of all moneys, either directly or through one or  more members of the Group made available to (i) that Belgian Guarantor and (ii) the  Subsidiaries of that Belgian Guarantor, in each case, irrespective of whether retained or  on-lent by the Belgian Guarantor or its Subsidiary.    (4) Release of Guarantee. Each New Guarantor’s Guarantee in respect of each  series of Notes shall terminate upon the Legal Defeasance or discharge of such series of Notes  pursuant to Article 4 or Section 13.2 of the Base Indenture, as the case may be.       

 

        (5) Severability. In case any provision of this Fourth Supplemental Indenture  shall be invalid, illegal or unenforceable, the validity, legality, and enforceability of the  remaining provisions shall not in any way be affected or impaired thereby.    (6) No Recourse Against Others. No director, officer, employee, incorporator  or stockholder of a New Perrigo Guarantor shall have any liability for any obligations of the  Company or the Guarantors (including a New Perrigo Guarantor) under the Outstanding Notes,  any Guarantees, the Indenture or this Fourth Supplemental Indenture or for any claim based on,  in respect of, or by reason of, such obligations or their creation. Each Holder by accepting  Outstanding Notes waives and releases all such liability. The waiver and release are part of the  consideration for issuance of the Outstanding Notes.    (7) Effect of Fourth Supplemental Indenture; Conflicts With Indenture. This  Fourth Supplemental Indenture is executed by the New Perrigo Guarantors, the Company and the  Trustee upon the Company’s request, pursuant to the provisions of the Indenture, and the terms  and conditions hereof shall be deemed to be part of the Indenture for all purposes. The Indenture,  as amended and supplemented by this Fourth Supplemental Indenture, is in all respects hereby  adopted, ratified and confirmed. Notwithstanding the foregoing, to the extent that any of the  terms of this Fourth Supplemental Indenture are inconsistent with, or conflict with, the terms of  the Indenture, the terms of this Fourth Supplemental Indenture shall govern.     (8) Trustee Disclaimer. The recitals contained in this Fourth Supplemental  Indenture shall be taken as the statements of the Company and the New Perrigo Guarantors and  the Trustee assumes no responsibility for their correctness. The Trustee makes no representations  as to and shall not be responsible for the validity or sufficiency of this Fourth Supplemental  Indenture or the Guarantees of the New Perrigo Guarantors. All rights, protections, privileges,  indemnities and benefits granted or afforded to the Trustee under the Indenture shall be deemed  incorporated herein by this reference and shall be deemed applicable to all actions taken,  suffered or omitted by the Trustee under this Fourth Supplemental Indenture.  (9) Counterparts; Electronic Signatures. This Fourth Supplemental Indenture  may be executed in any number of counterparts, each of which shall be an original but all of  which together shall constitute one instrument. Each counterparty may consist of a number of  copies hereof, each signed by less than all, but together signed by all, of the parties hereto. The  exchange of copies of this Fourth Supplemental Indenture and of signature pages by facsimile or  PDF transmission shall constitute effective execution and delivery of this Fourth Supplemental  Indenture as to the parties hereto and may be used in lieu of the original Fourth Supplemental  Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall  be deemed to be their original signatures for all purposes. This Fourth Supplemental Indenture  and any certificate, agreement or other document to be signed in connection with this  Supplemental Indenture and the transactions contemplated hereby shall be valid, binding, and  enforceable against a party when executed and delivered by an authorized individual on behalf of  the party by means of (i) an original manual signature; (ii) a faxed, scanned, or photocopied  manual signature, or (iii) any other electronic signature permitted by the federal Electronic  Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic  Transactions Act, and/or any other relevant electronic signatures law, including any relevant  provisions of the UCC (collectively, “Signature Law”), in each case to the extent applicable.  Each faxed, scanned, or photocopied manual signature, or other electronic signature, shall for all  

 

        purposes have the same validity, legal effect, and admissibility in evidence as an original manual  signature. Each party hereto shall be entitled to conclusively rely upon, and shall have no  liability with respect to, any faxed, scanned, or photocopied manual signature, or other electronic  signature, of any other party and shall have no duty to investigate, confirm or otherwise verify  the validity or authenticity thereof. This Fourth Supplemental Indenture may be executed in any  number of counterparts, each of which shall be deemed to be an original, but such counterparts  shall, together, constitute one and the same instrument. For the avoidance of doubt, original  manual signatures shall be used for execution or indorsement of writings when required under  the UCC or other Signature Law due to the character or intended character of the writings.    (10) Headings. The headings of the sections in this Fourth Supplemental  Indenture are for convenience of reference only and shall not be deemed to alter or affect the  meaning or interpretation of any provisions hereof.  [Signature Pages Follow]  

 

  [Signature Page to Supplemental Indenture No. 4]    IN WITNESS WHEREOF, the parties hereto have caused this Fourth Supplemental  Indenture to be duly executed, all as of the date first above written.  Perrigo Company plc    By:                                                    Name:  Sonia A. Hollies       Title:  Senior Vice President and Treasurer     

 

  [Signature Page to Supplemental Indenture No. 4]    IN WITNESS WHEREOF, the parties hereto have caused this Fourth Supplemental  Indenture to be duly executed, all as of the date first above written.  Perrigo Finance Unlimited Company    By:                                                    Name:  Sonia A. Hollies       Title:  Senior Vice President and Treasurer    

 

  [Signature Page to Supplemental Indenture No. 4]    IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental  Indenture to be duly executed, all as of the date first above written.           Perrigo Investments, LLC           Perrigo Investments Capital, Inc.         CP Kayak Holdings, Inc.           Elan Pharmaceuticals, LLC           PBM Nutritionals, LLC           Perrigo Diabetes Care, LLC           Perrigo International Holdings II, Inc.           Perrigo New York, Inc.  Perrigo Oral Health Care Holdings, Inc.  Ranir Global Holdings, LLC  Ranir, LLC  PBM Products, LLC  PBM Foods, LLC  PBM Canada Holdings, LLC  PBM China Holdings, LLC  Perrigo Mexico Investment Holdings, LLC  Perrigo International Holdings, LLC  Perrigo Florida, Inc.  Perrigo Direct, Inc.  Perrigo Americas Holdings, Inc.  Gr8ness, LLC  L. Perrigo Company  Perrigo Company   Perrigo Finance (US) LLC  Perrigo International, Inc.  Perrigo Management Company  Perrigo Research & Development Company  Perrigo Sales Corporation  PMI Branded Pharmaceuticals, Inc.      By:    Name: Sonia A. Hollies   Title:   Senior Vice President and  Treasurer              Athena Neurosciences, LLC      By:    Name: Sonia A. Hollies   Title:   President and Treasurer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]